Aevi Genomic Medicine, Inc. announced that it has expanded its collaboration with Kyowa Hakko Kirin Co., Ltd. with the signing of an option agreement for an early stage monoclonal antibody program ("program") in an ultra-orphan pediatric indication. Aevi Genomic Medicine and Kyowa Hakko Kirin have developed a collaboration framework to advance preclinical programs into the clinic, leveraging Aevi Genomic Medicine's expertise in rare and orphan pediatric diseases, and its ongoing collaboration with Children's Hospital of Philadelphia ("CHOP") and the biobank at the Center for Applied Genomics at CHOP. This new program will focus on an undisclosed, first-in-class monoclonal antibody targeting a specific cell surface marker implicated in an auto-immune ultra-orphan disease that primarily affects children.